Spots Global Cancer Trial Database for A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Official Title: A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Study ID: NCT00210340
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Annarita Conconi, MD
Affiliation: International Extranodal Lymphoma Study Group/Hematology Division. University Amedeo Avogadro. Novara
Role: STUDY_CHAIR
Name: Andres JM Ferreri, MD
Affiliation: Radiochemotherapy San Raffaele Hospital. Milan
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
